Genetic Inhibition of PKA Phosphorylation of RyR2 Prevents Dystrophic Cardiomyopathy
Overview
Affiliations
Aberrant intracellular Ca(2+) regulation is believed to contribute to the development of cardiomyopathy in Duchenne muscular dystrophy. Here, we tested whether inhibition of protein kinase A (PKA) phosphorylation of ryanodine receptor type 2 (RyR2) prevents dystrophic cardiomyopathy by reducing SR Ca(2+) leak in the mdx mouse model of Duchenne muscular dystrophy. mdx mice were crossed with RyR2-S2808A mice, in which PKA phosphorylation site S2808 on RyR2 is inactivated by alanine substitution. Compared with mdx mice that developed age-dependent heart failure, mdx-S2808A mice exhibited improved fractional shortening and reduced cardiac dilation. Whereas application of isoproterenol severely depressed cardiac contractility and caused 95% mortality in mdx mice, contractility was preserved with only 19% mortality in mdx-S2808A mice. SR Ca(2+) leak was greater in ventricular myocytes from mdx than mdx-S2808A mice. Myocytes from mdx mice had a higher incidence of isoproterenol-induced diastolic Ca(2+) release events than myocytes from mdx-S2808A mice. Thus, inhibition of PKA phosphorylation of RyR2 reduced SR Ca(2+) leak and attenuated cardiomyopathy in mdx mice, suggesting that enhanced PKA phosphorylation of RyR2 at S2808 contributes to abnormal Ca(2+) homeostasis associated with dystrophic cardiomyopathy.
Earl C, Javier A, Richards A, Markham L, Goergen C, Welc S Dis Model Mech. 2024; 17(10).
PMID: 39268580 PMC: 11488649. DOI: 10.1242/dmm.050852.
Gandhi S, Sweeney H, Hart C, Han R, Perry C Cells. 2024; 13(14.
PMID: 39056750 PMC: 11274633. DOI: 10.3390/cells13141168.
Earl C, Javier A, Richards A, Markham L, Goergen C, Welc S bioRxiv. 2024; .
PMID: 38659739 PMC: 11042272. DOI: 10.1101/2024.04.15.589650.
Haffner V, Nourian Z, Boerman E, Lambert M, Hanft L, Krenz M Am J Physiol Heart Circ Physiol. 2023; 325(5):H1168-H1177.
PMID: 37737731 PMC: 10907071. DOI: 10.1152/ajpheart.00265.2023.
Targeting p21-activated kinase 1 for development of a novel anti-arrhythmic drug class.
He Y, Grassam-Rowe A, Lei M, Bae J Philos Trans R Soc Lond B Biol Sci. 2023; 378(1879):20220285.
PMID: 37122206 PMC: 10150222. DOI: 10.1098/rstb.2022.0285.